A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

NCT05325866 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
260
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen